Real‐World Safety and Effectiveness of Evolocumab in Japanese Patients With Familial Hypercholesterolemia: Postmarketing Survey Analysis

BACKGROUND: Evidence on the real-world use of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors in familial hypercholesterolemia (FH) remains limited. This postmarketing surveillance study (NCT02808403) evaluated Japanese patients with FH and the long-term real-world effectiveness of evolocumab. METHODS: This analysis included patients with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Diagnostic pathways, patient characteristics, background lipid-lowering therapy, evolocumab use, low-density lipoprotein cholesterol (LDL-C) reduction, long-term target achievement, and findings in pediatric HoFH were assessed. RESULTS: Of 2117 patients in the safety analysis set (HeFH, n=2009; HoFH, n=108), 1380 (HeFH, n=1296; HoFH, n=84) were included in the effectiveness analysis. Compared with patients with HeFH, patients with HoFH had higher genetic testing rates (40.7% versus 9.8%), higher mean baseline LDL-C levels (188.4±107.3 mg/dL versus 139.2±58.3 mg/dL), and higher lipoprotein apheresis use (26.9% versus 2.1%), but fewer total comorbidities (2.2±1.5 versus 2.7±1.5). Statin use was similarly high in patients with HeFH and HoFH (92.2% and 93.5%, respectively) with many patients receiving low- to moderate-intensity statins. Most patients received evolocumab biweekly. LDL-C reductions were evident at 4 weeks and sustained at 104 weeks. At 104 weeks, mean LDL-C changes from baseline were -54.0% in patients with HeFH and -48.9% in patients with HoFH. LDL-C<70 mg/dL was achieved by 63.0% of patients with HeFH and 43.9% of patients with HoFH, and LDL-C<55 mg/dL was achieved by 48.2% and 17.1%, respectively. CONCLUSION: Evolocumab was associated with sustained LDL-C reductions over 104 weeks in Japanese patients with HeFH and HoFH, with higher target achievement in HeFH. Gaps exist in genetic testing and treatment optimization in routine Japanese FH care.

Authors

Institutions

Publication Details

Journal
Journal of the American Heart Association
Published
2026-11-18
DOI
https://doi.org/10.1161/jaha.126.050177
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real‐World Safety and Effectiveness of Evolocumab in Japanese Patients With Familial Hypercholesterolemia: Postmarketing Survey Analysis

Nobuhiro Osada, Mariko Harada‐Shiba, Masatsune Ogura, Hayato Tada et al.
1 links
Journal of the American Heart Association
Lipoproteins and Cardiovascular Health
article

Real‐World Safety and Effectiveness of Evolocumab in Japanese Patients With Familial Hypercholesterolemia: Postmarketing Survey Analysis

Nobuhiro Osada, Mariko Harada‐Shiba, Masatsune Ogura, Hayato Tada, Takahiro Yamashita, Feng Sheng
article en

Abstract

BACKGROUND: Evidence on the real-world use of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors in familial hypercholesterolemia (FH) remains limited. This postmarketing surveillance study (NCT02808403) evaluated Japanese patients with FH and the long-term real-world effectiveness of evolocumab. METHODS: This analysis included patients with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Diagnostic pathways, patient characteristics, background lipid-lowering therapy, evolocumab use, low-density lipoprotein cholesterol (LDL-C) reduction, long-term target achievement, and findings in pediatric HoFH were assessed. RESULTS: Of 2117 patients in the safety analysis set (HeFH, n=2009; HoFH, n=108), 1380 (HeFH, n=1296; HoFH, n=84) were included in the effectiveness analysis. Compared with patients with HeFH, patients with HoFH had higher genetic testing rates (40.7% versus 9.8%), higher mean baseline LDL-C levels (188.4±107.3 mg/dL versus 139.2±58.3 mg/dL), and higher lipoprotein apheresis use (26.9% versus 2.1%), but fewer total comorbidities (2.2±1.5 versus 2.7±1.5). Statin use was similarly high in patients with HeFH and HoFH (92.2% and 93.5%, respectively) with many patients receiving low- to moderate-intensity statins. Most patients received evolocumab biweekly. LDL-C reductions were evident at 4 weeks and sustained at 104 weeks. At 104 weeks, mean LDL-C changes from baseline were -54.0% in patients with HeFH and -48.9% in patients with HoFH. LDL-C<70 mg/dL was achieved by 63.0% of patients with HeFH and 43.9% of patients with HoFH, and LDL-C<55 mg/dL was achieved by 48.2% and 17.1%, respectively. CONCLUSION: Evolocumab was associated with sustained LDL-C reductions over 104 weeks in Japanese patients with HeFH and HoFH, with higher target achievement in HeFH. Gaps exist in genetic testing and treatment optimization in routine Japanese FH care.

Journal of the American Heart Association
Kanazawa University (JP), Osaka Medical and Pharmaceutical University (JP), Juntendo University (JP)
Amgen
Good health and well-being
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon